Idera Pharmaceuticals (IDRA) Receives Price Target

Idera Pharmaceuticals (IDRA) : The most positive equity analysts on Idera Pharmaceuticals (IDRA) expects the shares to touch $6, whereas, the least positive believes that the stock will trade at $4 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $5 with an expected fluctuation of $1.41 from the mean.

Idera Pharmaceuticals (IDRA) : 3 brokerage houses believe that Idera Pharmaceuticals (IDRA) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 3 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.


Idera Pharmaceuticals (NASDAQ:IDRA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.90 and $1.86 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.93. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.92, notching a gain of 0.52% for the day. The total traded volume was 301,359 . The stock had closed at $1.91 on the previous day.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company uses two drug discovery technology platforms to design and develop drug candidates. Using its Toll-like receptor (TLR) targeting technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its gene silencing oligonucleotide (GSO) technology, the Company is developing GSOs to turn off the messenger RNA (mRNA) associated with disease causing genes. The Companys drug candidates include IMO-8400 for Waldenstroms macroglobulinemia and diffuse large B-Cell lymphoma; IMO-2055/IMO-2125 for immune-oncology; IMO-8400 for dermatomyositis and Duchenne Muscular Dystrophy (DMD), and IMO-9200 for selected autoimmune disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.